KRN5500 FDA Approval Status
FDA Approved: No
Brand name: KRN5500
Company: Midatech Pharma US Inc.
Treatment for: Chronic Chemotherapy Induced Peripheral Neuropathy
KRN5500 is a novel, intravenous, non-opioid, non-narcotic compound in development for the treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics in patients with cancer.
Development timeline for KRN5500
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
